NASDAQ
ENLV
Last Price
US $6.05
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Enlivex Therapeutics Ltd. cash flow to debt ratio of -1.62K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial stability - Healthy cash flow growth.
Enlivex Therapeutics Ltd.'s free cash flow has increased -20.04% from $-13.11M last year to $-10.48M, signaling increasing performance
Financial stability - Healthy debt to equity ratio.
Enlivex Therapeutics Ltd.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial stability - Healthy debt to equity ratio development.
Enlivex Therapeutics Ltd.'s debt has decreased relative to shareholder equity from 0.02 last year to 0.00 today, signaling strengthened financials
Financial risk - Net debt/EBITDA.
Enlivex Therapeutics Ltd. has negative EBITDA, making leverage ratio unreliable
Financial stability - ICR.
Enlivex Therapeutics Ltd. earns at least as much interest as it pays. Interest obligations are fully covered.
Financial risk - Profit margin growth.
Enlivex Therapeutics Ltd. has insufficient data to evaluate this check.
Financial stability - Short term assets vs short term liabilities.
Enlivex Therapeutics Ltd.'s short-term assets of $1.74G exceed its short-term liabilities of $9.02M
Increasing performance - ROA.
Enlivex Therapeutics Ltd.'s return on assets of 53.10% is higher than the 5.00% threshold, indicating efficient asset utilization
Increasing performance - Absolute return on equity.
Enlivex Therapeutics Ltd.'s return on equity of 248.08%, is higher than 15.00%, indicating good performance
Decreasing performance - Earnings quality.
Enlivex Therapeutics Ltd.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Enlivex Therapeutics Ltd. had positive net income in only 1.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Enlivex Therapeutics Ltd. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Enlivex Therapeutics Ltd. has negative free cash flow, indicating cash burn
Increasing performance - Healthy earnings growth.
Enlivex Therapeutics Ltd.'s yearly earnings has increased -8.33K% since last year from $-15.01M to $1.24G, signaling increasing performance
Increasing performance - Healthy revenue growth.
Enlivex Therapeutics Ltd.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance
Decreasing performance - ROIC.
ROIC -0.49% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Decreasing performance - 3-year revenue CAGR.
Enlivex Therapeutics Ltd. has insufficient revenue history to calculate 3-year revenue CAGR.
Increasing performance - Revenue consistency.
Enlivex Therapeutics Ltd. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
Enlivex Therapeutics Ltd. had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Enlivex Therapeutics Ltd. has insufficient data to evaluate this check.
Undervalued - Earnings yield.
Enlivex Therapeutics Ltd. has an earnings yield of 6.74K%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings
Overvalued - EBITDA valuation.
Enlivex Therapeutics Ltd. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Enlivex Therapeutics Ltd. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Undervalued - PEG ratio value.
Enlivex Therapeutics Ltd. has a PEG-ratio under 1 which is considered undervalued
Undervalued - P/B ratio.
Enlivex Therapeutics Ltd. has a price-to-book ratio of 0.01x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Overvalued - P/S ratio.
Enlivex Therapeutics Ltd. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
248.08%
Return on equity
ROIC: -0.49%
Valuation History
0.02X
Price to Earnings
EV/EBITDA: -8.0X
Cash flow
Profit margin
-8.32%
(FY vs FY)
Cash flow Y/Y
2.78%
(FY vs FY)
Fair Value
Market $6.05
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.